Table 3.
Demographic and clinical characteristics for the different genotypes of rs10733113 in CD patients
| rs10733113 GG |
rs10733113 AG |
rs10733113 AA |
p value (Fisher or Kruskal–Wallis) | |
|---|---|---|---|---|
| Gender | ||||
| Male (n = 488) | 363 (50.9%) | 4 (57.1%) | 121 (46.4%) | 0.390 |
| Female (n = 493) | 350 (49.1%) | 3 (42.9%) | 140 (53.6%) | |
| Age at diagnosis [years] | ||||
| Median, q25–q75, | 24.7, 18.1–34.8, | 21.3, 15.3–32.2, | 23.4, 17.6–32.1, | 0.164 |
| Min–max | 1.1–81.4 | 9.0–40.1 | 0.8–81.0 | |
| Disease duration [years] | ||||
| Median, q25–q75, | 12.1, 7.0–20.7, | 7.5, 5.4–16.9, | 12.7, 6.8–23.5, | 0.462 |
| Min–max | 0.1–56.6 | 3.4–20.5 | 0.3–52.4 | |
| Complications* | ||||
| No (n = 345) | 259 (36.3%) | 4 (57.1%) | 82 (31.4%) | 0.185 |
| Yes (n = 636) | 454 (63.7%) | 3 (42.9%) | 179 (68.6%) | |
| Fistula, abscess or anal fissure* | ||||
| No (n = 518) | 376 (52.7%) | 4 (57.1%) | 138 (52.9%) | 1.000 |
| Yes (n = 463) | 337 (47.3%) | 3 (42.9%) | 123 (47.1%) | |
| Focus on the “yes”: | ||||
| Perianal fistula | 180 (53.4%) | 3 (100%) | 60 (48.8%) | 0.214 |
| Other fistula | 129 (38.3%) | 1 (33.3%) | 53 (43.1%) | 0.686 |
| Fissure | 102 (30.3%) | 1 (33.3%) | 37 (30.1%) | 1.000 |
| Abscess | 184 (54.6%) | 1 (33.3%) | 68 (55.3%) | 0.779 |
| Surgery for fistula | 178 (52.8%) | 1 (33.3%) | 67 (54.5%) | 0.753 |
| Stenosis* | ||||
| No (n = 551) | 403 (56.5%) | 4 (57.1%) | 144 (55.2%) | 0.916 |
| Yes (n = 430) | 310 (43.5%) | 3 (42.9%) | 117 (44.8%) | |
| Focus on the “yes”: | ||||
| Operation | 153 (49.4%) | 0 (0%) | 68 (58.1%) | 0.045 |
| Dilation | 117 (37.7%) | 2 (66.7%) | 50 (42.7%) | 0.359 |
| No intervention | 170 (54.8%) | 1 (33.3%) | 65 (55.6%) | 0.772 |
| CDAI**—maximal value throughout follow-up | ||||
| Median, q25–q75, | 63, 28–112, | 73, 20–76, | 76, 33–129, | 0.024 |
| Min–max | 2–435 | 6–81 | 0–479 | |
| Reported flare* | ||||
| No (n = 477) | 355 (49.8%) | 4 (57.1%) | 118 (45.2%) | 0.369 |
| Yes (n = 504) | 358 (50.2%) | 3 (42.9%) | 143 (54.8%) | |
| Flare possibly or highly related to (focus on yes): | ||||
| NSAIDs | 9 (2.5%) | 0 (0%) | 2 (1.4%) | 0.753 |
| Antibiotics | 8 (2.2%) | 0 (0%) | 1 (0.7%) | 0.485 |
| GI tract infection | 54 (15.1%) | 0 (0%) | 30 (21.0%) | 0.203 |
| Other infection | 23 (6.4%) | 0 (0%) | 14 (9.8%) | 0.357 |
| Treatment decr./disc | 89 (24.9%) | 1 (33.3%) | 44 (30.8%) | 0.338 |
| Other medication | 4 (1.1%) | 0 (0%) | 3 (2.1%) | 0.437 |
| Flare management (focus on the yes): | ||||
| Hospitalization | 61 (17.0%) | 1 (33.3%) | 24 (16.8%) | 0.598 |
| Ambulatory | 88 (24.6%) | 0 (0%) | 41 (28.7%) | 0.468 |
| Surgery | 37 (10.3%) | 0 (0%) | 13 (9.1%) | 0.813 |
| Drug therapy | 308 (86.0%) | 3 (100%) | 127 (88.8%) | 0.650 |
| Focus on the hospitalizations: | ||||
| Total days of hosp. | 7, 2–17, | 0, 0–0, | 4.5, 1–13.5, | 0.386 |
| Median, q25–q75, | 0–55 | 0–0 | 0–86 | |
| Min–max | ||||